A day after it announced a big-ticket acquisition in the US, drugmaker Lupin has entered into an agreement with Temmler Pharma GmbH to acquire its specialty product portfolio, for an undisclosed sum.

Germany-based Temmler is part of the Aenova Group, a large pharmaceutical contract manufacturer, and has a specialty portfolio of 13 products. They include Central Nervous System (CNS) products and specialty products that address rare disease areas like Myasthenia Gravis, Huntington disease as well as fast-growing dermatology products for anti-wart treatment, Lupin said.

Since Huntington disease has many symptoms ranging from motoric symptoms to personality changes, both Temmler and Hormosan products can be used to treat the disease, it added.

In 2008, Lupin had acquired Germany’s Hormosan Pharma, a sales and marketing generics company that specialised in supplying CNS medicines. On the latest acquisition, Vinita Gupta, Lupin Chief Executive, said in a statement that Temmler’s business had a strong strategic fit with Lupin’s Hormosan business in Germany and enables Lupin to bring an enhanced specialty CNS portfolio to the German market.

On Thursday, Lupin had acquired US-based firm Gavis for $880 million, making it Lupin’s third acquisition in two months. Interacting with the media after the US acquisition, Gupta had indicated that the company’s appetite for acquisitions had not been satiated and that more were on the cards in Europe and the US, possibly of speciality products.

Related Topics